Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons.
作者信息
Gangat Naseema, Tefferi Ayalew
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
出版信息
Blood Cancer J. 2025 May 7;15(1):91. doi: 10.1038/s41408-025-01302-z.
Abstract
摘要
相似文献
1
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons.初治的骨髓纤维化患者使用莫洛替尼：利弊分析
Blood Cancer J. 2025 May 7;15(1):91. doi: 10.1038/s41408-025-01302-z.
2
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.莫米松替比 versus 持续芦可替尼或 JAK 抑制剂治疗经验的骨髓纤维化伴贫血患者的最佳可用治疗：SIMPLIFY-2 的亚组分析。
Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11.
3
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.莫洛替尼与达那唑治疗有症状的贫血和骨髓纤维化患者的疗效对比（MOMENTUM）：一项国际、双盲、随机、对照3期研究的结果
Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0.
4
Momelotinib for the treatment of myelofibrosis with anemia.莫雷洛替尼治疗伴贫血的骨髓纤维化。
Future Oncol. 2022 Jun;18(20):2559-2571. doi: 10.2217/fon-2022-0276. Epub 2022 May 23.
5
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.SIMPLIFY-1 和 SIMPLIFY-2 期临床试验中，芦可替尼治疗骨髓纤维化患者的总生存情况。
Leukemia. 2022 Sep;36(9):2261-2268. doi: 10.1038/s41375-022-01637-7. Epub 2022 Jul 22.
6
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.用莫洛替尼治疗的初治或经治JAK抑制剂的骨髓纤维化患者输血强度的纵向评估
Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):199-211. doi: 10.1016/j.clml.2024.10.001. Epub 2024 Oct 16.
7
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.Momelotinib用于血小板减少的骨髓纤维化患者：三项随机3期试验的事后分析
Hemasphere. 2023 Oct 27;7(11):e963. doi: 10.1097/HS9.0000000000000963. eCollection 2023 Nov.
8
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.SIMPLIFY-1 试验中根据基线血红蛋白水平的骨髓纤维化患者亚组中的 Momelotinib 与 Ruxolitinib 的比较。
Leuk Lymphoma. 2024 Jul;65(7):965-977. doi: 10.1080/10428194.2024.2328800. Epub 2024 Mar 19.
9
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.SIMPLIFY-1：一项在初治的骨髓纤维化患者中比较莫洛替尼与芦可替尼的III期随机试验。
J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.
10
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.Momelotinib 的长期安全性和生存获益：3 期随机对照临床试验的综合分析。
Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311.
本文引用的文献
1
Acute Megakaryoblastic Leukemia Masquerading as a Germ Cell Tumor.伪装成生殖细胞肿瘤的急性巨核细胞白血病
Am J Hematol. 2025 Apr 28. doi: 10.1002/ajh.27698.
2
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.Momelotinib治疗骨髓纤维化贫血患者的真实世界结局：MOMGEMFIN研究结果
Blood Cancer J. 2025 Apr 17;15(1):67. doi: 10.1038/s41408-025-01275-z.
3
Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases.真性红细胞增多症的细胞遗传学异常：669例有效病例的表型相关性及预后意义
Haematologica. 2025 Mar 27. doi: 10.3324/haematol.2025.287569.
4
Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials.60名在梅奥诊所接受治疗但未参加临床试验的骨髓纤维化患者对帕西替尼治疗的反应及生存的预测因素。
Haematologica. 2025 Mar 20. doi: 10.3324/haematol.2025.287576.
5
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.骨髓纤维化和骨髓增生异常综合征中贫血的新兴发病机制及新药
Am J Hematol. 2025 Jun;100 Suppl 4:51-65. doi: 10.1002/ajh.27659. Epub 2025 Mar 8.
6
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.修订版国际工作组-欧洲白血病网骨髓纤维化贫血反应标准的提案。
Blood. 2024 Oct 24;144(17):1813-1820. doi: 10.1182/blood.2024025802.
7
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.莫雷利夫 - 真实世界数据支持莫洛替尼作为治疗细胞减少性骨髓纤维化患者的安全有效治疗选择的潜力。
Ann Hematol. 2024 Oct;103(10):4065-4077. doi: 10.1007/s00277-024-05908-4. Epub 2024 Jul 29.
8
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.芦可替尼治疗骨髓纤维化患者贫血的安全性和有效性。
Blood Adv. 2024 Sep 10;8(17):4511-4522. doi: 10.1182/bloodadvances.2024012939.
9
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.Momelotinib用于治疗骨髓纤维化：我们对100例临床试验患者的14年经验及美国食品药品监督管理局近期的批准。
Blood Cancer J. 2024 Mar 18;14(1):47. doi: 10.1038/s41408-024-01029-3.
10
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.帕克里替尼是一种有效的 ACVR1 抑制剂，可显著改善骨髓纤维化患者的贫血症状。
Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151.
Zotero 插件